Published in Immun Infekt on February 01, 1988
Temporary withdrawal of immunosuppression for life-threatening infections after liver transplantation. Transplantation (1994) 0.91
Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci (1992) 2.47
Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-gamma. J Immunol (1991) 1.00
Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc (1999) 0.99
Selective reduction of donor-specific cytotoxic T lymphocyte precursors in patients with a well-functioning kidney allograft. Transplantation (1987) 0.95
Possible association of the immunosuppressive and B cell lymphoma-promoting properties of cyclosporine. Transplantation (1990) 0.94
Human cytotoxic T lymphocytes. I. Limiting-dilution analysis of alloreactive cytotoxic T-lymphocyte precursor frequencies. Scand J Immunol (1985) 0.94
Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation. Proc Natl Acad Sci U S A (1989) 0.88
Mycophenolate mofetil monotherapy: an example of a safe nephrotoxicity/atherogenicity-free immunosuppressive maintenance regimen in a selected group of kidney-transplanted patients. Transplant Proc (2000) 0.84
An inherited deficiency of the third component of complement, C3, in guinea pigs. Eur J Immunol (1986) 0.83
C3a induced activation and stimulus specific reversible desensitization of guinea pig platelets. Agents Actions Suppl (1982) 0.81
Restricted T cell V beta repertoire in renal allografts during acute and chronic rejection. Kidney Int (1996) 0.81
Pharmacokinetics of FK 506 and mycophenolic acid after the administration of a FK 506-based regimen in combination with mycophenolate mofetil in kidney transplantation. Transplant Proc (1998) 0.80
A kinetic analysis of the effects of interleukin-2 diphtheria toxin fusion protein upon activated T cells. Transplantation (1990) 0.79
Quantitative assessment of interleukin-2-producing alloreactive human T cells by limiting dilution analysis. J Immunol Methods (1988) 0.79
Transcriptional modulation of human IL-6 gene expression by verapamil. J Immunol (1990) 0.79
Interleukin-7 (IL-7) and its effect on the expression of the intercellular adhesion molecule (ICAM-1) in T cells. Transplant Proc (1991) 0.78
The role of interleukin-6 in mitogenic T-cell activation: detection of interleukin-2 heteronuclear RNA by polymerase chain reaction. Cell Immunol (1991) 0.78
Human cytotoxic T lymphocytes. II. Frequency analysis of cyclosporin A-sensitive alloreactive cytotoxic T-lymphocyte precursors. Immunology (1987) 0.77
No clinical evidence of hyperlipidemia as a risk factor for chronic renal allograft failure. Transplant Proc (1999) 0.77
Low zone desensitization: a stimulus-specific control mechanism of cell response. Investigations on anaphylatoxin-induced platelet secretion. J Exp Med (1982) 0.77
The molecular basis for the synergism between the CD3/alpha beta T cell receptor and the CD2 antigen-derived signals in promoting T-cell proliferation. Transplantation (1991) 0.77
Clonal reduction of CTL-P and acquired allograft tolerance in various human transplantation models. Transplant Proc (1990) 0.77
Nephrotoxicity-free, mycophenolate mofetil-based induction/maintenance immunosuppression in elderly recipients of renal allografts from elderly cadaveric donors. Transplant Proc (2000) 0.76
[Baclofen intoxication in chronic hemodialysis and kidney transplantation]. Dtsch Med Wochenschr (1992) 0.76
Physiologic signaling in normal human T-cells: mRNA phenotyping by northern blot analysis and reverse transcription-polymerase chain reaction. Cell Immunol (1990) 0.75
Influence of macrophage activation on the synthesis of complement components C2, C3, C4. Adv Exp Med Biol (1982) 0.75
Hyperimmunoglobulin prophylaxis, monitoring and preemptive ganciclovir treatment eliminate the risk of CMV infection to improve patient and renal allograft survival. Transpl Int (2000) 0.75
Aggressive treatment of the first acute rejection episode using first-line anti-lymphocytic preparation reduces further acute rejection episodes after human kidney transplantation. Transpl Int (1998) 0.75
Similar effects of cyclosporine and verapamil on lymphokine, interleukin 2 receptor, and proto-oncogene expression. Transplantation (1989) 0.75
[The immunobiology of transplant rejection and its pharmacological modification]. Dtsch Med Wochenschr (1991) 0.75
Tacrolimus as a primary immunosuppressive therapy in cadaveric renal transplantation: five years' experience at a single center. Transplant Proc (1998) 0.75
Co-administration of tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. Transplant Proc (1998) 0.75
[Evaluating transplant kidneys: nuclear magnetic resonance tomography in comparison with sonography]. Rontgenblatter (1987) 0.75